MiNK Therapeutics (INKT)
NASDAQ:INKT
Want to see INKT full AI Analyst Report?
Top Page
MiNK Therapeutics
(NASDAQ:INKT)
Select Model
Select Model
Rating:49Neutral
Price Target:
$12.00
▼(-15.55% Downside)
Action:Reiterated
Date:05/16/26
Overall score is constrained primarily by weak financial performance (no revenue, persistent losses, negative cash flow, and negative equity/volatility). Technicals also lean bearish with the stock below key moving averages and negative MACD. These are partially offset by a relatively positive earnings-call outlook tied to randomized ARDS trial initiation, near-term data expectations, and manufacturing/partnership progress, while valuation inputs are limited given negative earnings and no dividend yield provided.
Positive Factors
Remarkable survival signal
An unusually long median OS (>23 months) in heavily pretreated, checkpoint‑refractory gastric cancer is a durable efficacy signal for the iNKT platform. Such a signal can materially de‑risk programs, attract partnerships, and improve probability of advancing assets across indications over the next 2–6 months.
Negative Factors
Limited cash runway
Modest cash relative to multi‑site randomized trials and ongoing programs restricts operational flexibility. Over the next 2–6 months the company may need to secure non‑dilutive deals or equity financing; failure or delay in financing could slow enrollment, development pace, or force unfavorable terms that dilute long‑term shareholder value.
Read all positive and negative factors
Positive Factors
Negative Factors
Remarkable survival signal
An unusually long median OS (>23 months) in heavily pretreated, checkpoint‑refractory gastric cancer is a durable efficacy signal for the iNKT platform. Such a signal can materially de‑risk programs, attract partnerships, and improve probability of advancing assets across indications over the next 2–6 months.
Read all positive factors
MiNK Therapeutics (INKT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$60.78M
Dividend YieldN/A
Average Volume (3M)39.56K
Price to Earnings (P/E)―
Beta (1Y)0.09
Revenue GrowthN/A
EPS Growth-13.32%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.83
Shares Outstanding4,981,899
10 Day Avg. Volume31,712
30 Day Avg. Volume39,559
Financial Highlights & Ratios
PEG Ratio-3.68
Price to Book (P/B)-3.35
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-306.82
Enterprise Value/Ebitda-4.12
Forecast
1Y Price Target
$35.00Price Target Upside146.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.27
Revenue Forecast (FY)N/A
MiNK Therapeutics Business Overview & Revenue Model
Company Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-media...
How the Company Makes Money
MiNK Therapeutics does not have consistent commercial product sales and, as a clinical-stage company, its operations have primarily been funded through external financing rather than recurring operating revenue. The company may generate revenue fr...
MiNK Therapeutics Earnings Call Summary
Earnings Call Date:May 15, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call communicates strong scientific and early clinical momentum: context-dependent mechanistic data, an unusually long median overall survival signal in refractory gastric cancer (>23 months), initiation of a randomized 90‑patient Phase II ARDS trial with a seamless Phase II/III design, scalable off‑the‑shelf manufacturing, and partnerships that reduce dilution. Offsetting risks include a modest cash balance (~$9.5M), ongoing operating losses, the early-stage nature of much of the efficacy data (investigator trials, translational findings, case reports), and typical ARDS and trial execution risks (biologic heterogeneity, prior failures in cell therapy, logistical/geopolitical complexities). On balance, the highlights (clinical signal, trial initiation, manufacturing readiness, partnerships and planned near‑term readouts) outweigh the lowlights, but execution and financing will be critical over the next 12 months.Positive Updates
Robust Translational and Clinical Presentations
Presented data at 4 major scientific meetings (pulmonary fibrosis, AACR, ASGCT, ATS) showing coherent biology across cancer, severe lung injury, fibrosis and immune dysregulation; translational analyses demonstrate context-dependent immune outputs (TH1/tumor-killing in cancer vs restoration-oriented signaling in ARDS) from the same donor-derived agent 797 product.
Negative Updates
Limited Cash Position and Near-Term Financing Risk
Quarter-end cash approximately $9.5M (down from $13.4M at end of 2025, a ~29.1% decrease); while management states ~12 months runway, current cash is modest given multiple ongoing programs and upcoming trial execution needs.
Read all updates
Q1-2026 Updates
Positive
Negative
Robust Translational and Clinical Presentations
Presented data at 4 major scientific meetings (pulmonary fibrosis, AACR, ASGCT, ATS) showing coherent biology across cancer, severe lung injury, fibrosis and immune dysregulation; translational analyses demonstrate context-dependent immune outputs (TH1/tumor-killing in cancer vs restoration-oriented signaling in ARDS) from the same donor-derived agent 797 product.
Read all positive updates
Company Guidance
On the call management provided guidance that the randomized Phase II ARDS trial has been initiated as a 1:1 randomized study of 90 patients (≈45 per arm) with endpoints including overall survival, ventilator‑free days and ICU/ventilator days, configured as a seamless Phase II/III pathway with an FDA interaction in the coming weeks and preliminary readouts expected in H2 2026 (substantial data before year‑end); they reiterated they have treated ~100 patients to date across programs, reported a median overall survival >23 months in the primary cohort of refractory gastric cancer, have presented at 4 major scientific meetings so far, have manufacturing material largely in hand (scalable to billions of cells per donor) to limit further manufacturing burn, and summarized Q1 2026 financials of a net loss of ~$2.7M ($0.57/share), quarter‑end cash of ≈$9.5M after repaying ~$5.2M of convertible notes and raising ~$3M in Q1, with an asserted operational runway of at least 12 months.MiNK Therapeutics Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
9
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -181.75K | -215.44K | -204.62K | -121.75K | -77.96K |
| EBITDA | -12.31M | -10.57M | -22.25M | -27.87M | -27.70M |
| Net Income | -12.49M | -10.78M | -22.46M | -27.99M | -30.21M |
Balance Sheet | |||||
| Total Assets | 14.24M | 5.72M | 4.55M | 21.47M | 40.24M |
| Cash, Cash Equivalents and Short-Term Investments | 13.36B | 4.58M | 3.37M | 19.64M | 38.89M |
| Total Debt | 5.18M | 4.92M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 28.47M | 25.31M | 22.61M | 21.87M | 16.47M |
| Stockholders Equity | -14.23M | -19.59M | -18.06M | -401.30K | 23.78M |
Cash Flow | |||||
| Free Cash Flow | -5.93B | -9.56M | -15.84M | -19.12M | -13.08M |
| Operating Cash Flow | -5.93B | -9.56M | -15.76M | -18.87M | -12.83M |
| Investing Cash Flow | 0.00 | 0.00 | -73.56K | -250.05K | -248.98K |
| Financing Cash Flow | 14.72B | 10.82M | -407.17K | -155.60K | 49.26M |
MiNK Therapeutics Technical Analysis
Positive
14.21
Price Trends
11.12
Positive
11.25
Positive
12.39
Negative
Market Momentum
>-0.01
Negative
59.07
Neutral
68.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INKT, the sentiment is Positive. The current price of 14.21 is above the 20-day moving average (MA) of 11.04, above the 50-day MA of 11.12, and above the 200-day MA of 12.39, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 59.07 is Neutral, neither overbought nor oversold. The STOCH value of 68.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INKT.
MiNK Therapeutics Risk Analysis
MiNK Therapeutics disclosed 76 risk factors in its most recent earnings report. MiNK Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
MiNK Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $162.48M | 1.47 | 60.96% | ― | -100.00% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $60.78M | -4.69 | 76.02% | ― | ― | -13.32% | |
46 Neutral | $38.04M | -3.64 | -53.43% | ― | -100.00% | 63.20% | |
43 Neutral | $18.75M | -0.17 | 7743.57% | ― | ― | 35.04% | |
42 Neutral | $299.93M | -1.06 | 162.59% | ― | 10.70% | -66831.90% |
* Healthcare Sector Average
INKT
MiNK Therapeutics
12.20
5.03
70.15%
VERU
Veru
2.37
-3.40
-58.93%
ORMP
Oramed Pharm
3.97
1.75
78.99%
ARMP
Armata Pharmaceuticals
8.17
6.23
321.13%
QNCX
Quince Therapeutics
1.15
-9.45
-89.15%
MiNK Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
MiNK Therapeutics Explores Strategic Partnerships and Trial Collaborations
Positive
Mar 27, 2026
In response to recent investor inquiries, MiNK Therapeutics clarified that it is in active discussions with multiple parties about potential clinical combination trials involving agenT-797, its proprietary allogeneic iNKT cell therapy. The company...
Business Operations and StrategyExecutive/Board Changes
MiNK Therapeutics Appoints New Principal Financial and Accounting Officers
Neutral
Mar 19, 2026
On March 13, 2026, MiNK Therapeutics appointed Melissa Orilall, currently Vice President of Global Financial Operations at Agenus Inc., as its Principal Financial Officer, formalizing her oversight of general accounting, close procedures, and fina...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.